BIO-Europe more popular than ever More than 4,000 participants from all over the globe visited Berlin in early November to take part in this years BIO-Europe. The event continues to be on the upswing – like the biotech industry itself. more ➔
Spain pushes circular bioeconomyConversion of agricultural waste into useful products is a worldwide need. As part of the European Project Valor Plus, Spanish biotechindustry association ASEBIO invited its members to visit the recently … more ➔
Stem cells cure deadly human skin diseaseFor the first time researchers at universities Bochum (Germany), Salzburg (Austria), and Modena (Italy) have shown that autologous transgenic keratinocyte cultures can regenerate an entire, fully functional … more ➔
InflaRx Announces Pricing of Initial Publi... German inflammation and autoimmunity specialist InflaRx AG (Jena) announced it will offer 6,667,000 common shares at an Nasdaq initial public offering price of $15.00 per common share, resulting in … more ➔
FDA lifts clinical hold on Cellectis Phase...The US Food and Drug Administration (FDA) has lifted the clinical hold due to a patient death on Phase I testing of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm … more ➔
MAB Discovery expands 2013 partnership wit... German MAB Discovery GmbH has extended its 2013 collaboration with BioNTech AG by a contract to produce another set of therapeutic antibodies against a range of targets delivered by BioNTec. more ➔
European biotech stocks: New wave of optim...In 2017, the European biotech sector witnessed a volume increase in IPOs and follow-on financings. This says the most recent capital market report of BIOCOM which is published during BIO-Europe on November … more ➔
NousCom raises €42mSwiss oncolytic virus and vaccine specialist NousCom has closed a €42m Series B financing round led by new investor Abingworth. Co-investors include new 5AM Ventures, and existing investors LSP and … more ➔
Blocking antibody recycling vs autoimmune...Researchers at Belgian UCB SA have clinically demonstrated that an antibody targeting a normal cellular recycling process can remove autoantibodies from the blood of people with autoimmune diseases. … more ➔
Another death related to allogenic CAR-T c...Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trials with UCART123, French Cellectis SAs allogenic CAR-T therapies. … more ➔
